A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Recruiting now

Conditions studied: Obstructive Hypertrophic Cardiomyopathy

In brief

The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.

Key facts

Study ID

NCT06146660

Run by

Bristol-Myers Squibb

People needed

600

Starts

2024-07-24

Expected to finish

2026-11-30

Last updated by the study team

2024-11-06

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult participants 19 years of age or older
• Participants who receive mavacamten according to the approved product label
• Participants who sign the informed consent form

You may not qualify if…

• Participants who are prescribed mavacamten for therapeutic indications not approved in Korea
• Participants for whom mavacamten is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety

Where it is running

• Novotech Laboratory Korea Co., Ltd. — Seoul, South Korea (enrolling)
• Local Institution - 0001 — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.